Navigation Links
ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
Date:7/24/2012

EXTON, Pa., July 24, 2012 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2012 are expected to be released no later than Thursday, August 9, 2012.  In light of the August 9th PDUFA date for industrial scale expansion of Cinryze® (C1 esterase inhibitor [human]), the company has chosen to align the two events. In the event the company receives a response from the FDA prior to August 9th, the company will announce the specific timing of the conference call upon receipt of the FDA response.

During the conference call, ViroPharma management will discuss the 2012 second quarter financial results and other business including the FDA decision regarding industrial scale expansion of Cinryze.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until August 23, 2012.  To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call. 

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
2. ViroPharma To Participate In The JMP Securities Healthcare Conference
3. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
4. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
5. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
6. Top 100 Drug Sales Data Released - Plavix Leads the Way
7. Berkery Noyes Releases First Half 2012 M&A Report For the Healthcare/Pharma Information and Technology Industry
8. Medica Announces Global Release of the EasyCell Assistant Analyzer for Hematology Laboratories
9. Merit Medical Systems Announces Earnings Release Date/Time And Conference Call Information For The Second Quarter Ended June 30, 2012
10. Span-America Medical Systems To Release Third Quarter Results On August 2, 2012
11. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
(Date:5/24/2016)... 2016  Diana Russell suffers from a form of ... inside out.  This disease has put her in a ... and grandchildren to leave her home.  Because of the ... haul the wheelchair.  So if there is a family ... is left to wait for the bus. ...
(Date:5/24/2016)... May 24, 2016 The ... world , s first dual therapy stent, ...   OrbusNeich, a global company specializing in ... portfolio to include products to treat peripheral artery disease. ... first entry devices for lower limb and arteriovenous (AV) ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... An April Gallup survey found rising health care costs to ... Sun Health Senior Living (SHSL) may not share those same worries thanks to ... for the year, while holding the line on increasing their contributions, including premiums, deductibles ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life Science ... the organization has earned its ISO 13485 certification, indicating the company’s quality control ... rules and policies associated with ISO quality standard 13485. , BSI Group ...
(Date:5/26/2016)... Texas (PRWEB) , ... May 26, 2016 , ... ... Friday, May 13 at Blackhorse Golf Club in Cypress. With the help of community ... non-profit that restores, empowers, and renews hope for wounded service members and their families ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management and ... Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI Institute ... of the Institute for Functional Medicine. , He also heads up FITTLab, the comprehensive ...
(Date:5/26/2016)... ... ... Bunion Bootie , the manufacturer of the newest and best in ... customer demand over the Mother’s Day Weekend promotion. So much so, that they completely ... completely replenished its inventory levels, it hopes to continue its current sales pace, and ...
Breaking Medicine News(10 mins):